<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129411</url>
  </required_header>
  <id_info>
    <org_study_id>19-005486</org_study_id>
    <nct_id>NCT04129411</nct_id>
  </id_info>
  <brief_title>Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation</brief_title>
  <official_title>Pilot Study for the Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to
      treat papillary thyroid carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators plan to identify patients with small papillary thyroid carcinoma and subject
      such patients to radiofrequency ablation (RFA) therapy.

      Following RFA procedure patients will be monitored to study the changes in primary tumor
      volume, development of lymph node involvement, development of distant metastasis and changes
      in serum thyroid hormone levels.

      Investigators will also assess the stability of these changes (need for repeat therapy) and
      the safety of the RFA procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label single interventional series</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in thyroid nodule size (overall volume measured in percentage)</measure>
    <time_frame>18 months</time_frame>
    <description>Thyroid tumor volume shrinkage in percentage will be assessed by ultrasound and compared with pre-procedure volume.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain related to RFA procedure</measure>
    <time_frame>1-2 months</time_frame>
    <description>McGill Pain Questionnaire (Pain intensity scale: 0 = none, 1 = mild, 2 = moderate or 3 = severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of lymph node involvement</measure>
    <time_frame>18 months</time_frame>
    <description>Cervical adenopathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of distant metastasis</measure>
    <time_frame>18 months</time_frame>
    <description>Distant metastatic sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the RFA procedure</measure>
    <time_frame>1-2 months</time_frame>
    <description>Evaluation of site of RFA for local complication and asses pain with McGill Pain Questionnaire (Pain intensity scale: 0 = none, 1 = mild, 2 = moderate or 3 = severe)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Papillary Thyroid Cancer</condition>
  <condition>Papillary Thyroid Microcarcinoma</condition>
  <arm_group>
    <arm_group_label>RFA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RFA</intervention_name>
    <description>Radiofrequency ablation of selectively targeted thyroid nodule to treat papillary thyroid cancer.</description>
    <arm_group_label>RFA Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are adults

          -  Nodule with Papillary thyroid carcinoma meeting the below criteria:

               -  Diagnosed by FNA cytology.

               -  Size &lt; 1.5 cm

               -  Non-surgical therapy is considered acceptable by the treating physician

               -  Radiology evaluation deems the lesion amenable to RFA therapy with minimal risk
                  of complication

        Exclusion Criteria:

          -  Clinical evidence for a multifocal papillary thyroid malignancy

          -  Clinical evidence for local or distant metastatic disease

          -  Pregnancy

          -  Vocal cord paralysis on contralateral side

          -  Coagulopathy or patients on anticoagulation therapy

          -  Patients with prior neck surgery or neck radiation

          -  Patients with neck anatomy that precludes easy access by RFA

          -  Patients with comorbidities deemed too high of a risk for general anesthesia

          -  Treatment with another investigational drug or intervention (within 6 weeks of planned
             RFA).

          -  Current drug or alcohol use or dependence that, in the opinion of the site
             investigator, would interfere with adherence to study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marius Stan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marius Stan, MD</last_name>
    <phone>507-284-2463</phone>
    <email>stan.marius@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vishakantha Murthy, PhD., MBA</last_name>
    <phone>507-255-8112</phone>
    <email>Murthy.Vishakantha@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marius Stan, MD</last_name>
      <phone>507-284-2463</phone>
      <email>stan.marius@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vishakantha Murthy, PhD., MBA</last_name>
      <phone>507-255-8112</phone>
      <email>Murthy.Vishakantha@mayo.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Marius Stan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>RFA</keyword>
  <keyword>Radiofrequency</keyword>
  <keyword>Thyroid Cancer</keyword>
  <keyword>Ablation techniques</keyword>
  <keyword>Ultrasonography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

